<DOC>
	<DOCNO>NCT00302822</DOCNO>
	<brief_summary>HIV infection diagnose late substantial proportion patient increase risk clinical progression ( AIDS , new AIDS-defining event death ) . The currently recommended antiretroviral therapy suboptimal activity set potent quadruple-drug therapy sufficiently evaluate . Enfuvirtide may appropriate candidate fourth antiretroviral agent , regard activity , parenteral administration avoid gastrointestinal symptom often lead interruption treatment , lack pharmacokinetic interaction absence systemic toxicity . The aim study investigate , comparative intensification trial , immunological benefit add enfuvirtide 6 month conventional antiretroviral therapy HIV-1 infect severely immunosuppressed patient , naïve antiretroviral treatment . We postulate addition enfuvirtide first-line antiretroviral therapy consist emtricitabine/tenofovir combine either efavirenz lopinavir/r may improve immunological restoration , measure proportion patient 200 CD4 cell per mm3 24 week antiretroviral therapy .</brief_summary>
	<brief_title>Intensification With Enfuvirtide Naive HIV-infected Patients ( ANRS130 )</brief_title>
	<detailed_description>The purpose randomize , open-label study evaluate immunological efficacy two first-line strategy antiretroviral therapy : 1. emtricitabine/tenofovir disoproxil fumarate coformulated plus efavirenz ( lopinavir/r ) intensify enfuvirtide first 24 week therapy . 2. emtricitabine/tenofovir disoproxil fumarate coformulated plus efavirenz ( lopinavir/r ) Patients lymphocytes T CD4+ cell ( CD4 ) count 100 per mm3 , CD4 cell count 200 per mm3 past history presence AIDS define event naïve antiretroviral therapy eligible . This multicenter study enroll 220 patient ( n=110 arm ) . The planned duration study 48 week enrolment last subject . The primary endpoint immunological success define CD4 cell count 200 cell per mm3 24 week initial treatment . The durability response evaluate patient follow 48 week .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Enfuvirtide</mesh_term>
	<criteria>Antiretroviral naïve HIV1 infect patient CD4 cell count 100 per mm3 , CD4 cell count 200/mm3 past history presence B C ( AIDS define ) event Signed informed consent Pregnancy ; breast feeding Coinfection HIV2 infection HIV1 subtype O Antiretroviral pretreated patient Neoplasia disease currently treat chemotherapy radiotherapy Severe liver failure Treatment cytokine HIV vaccine trial One follow biological abnormality : hemoglobin 10 g/dl , Neutrophils 750 per mm3 , thrombocytopenia 50000 per mm3 , creatinine clearance 60 ml per min , Liver Function Tests 3 Upper Limit Normal</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>HIV infection</keyword>
	<keyword>Fuzeon</keyword>
	<keyword>Truvada</keyword>
	<keyword>AIDS</keyword>
	<keyword>Treatment Naive</keyword>
</DOC>